Enzymatic removal of the sialic acid moiety of HPIV receptors inhibits infection with all tested HPIV strains, both in vitro and in cotton rats. Enzyme-mediated removal of sialic acid receptors represents a novel antiviral strategy for HPIV. The results of this study raise the possibility of a broad spectrum antiviral agent for influenza virus and [...]
Read the full article →
CPL Biologicals (CPLB), a joint venture of Ahmedabad based Cadila Pharmaceuticals Ltd and US based Novavax Inc has completed construction of its vaccine facility at Dholka near Ahmedabad that can produce up to 60 million doses of vaccines every year. The company said this in an announcement to Nasdaq. A spokesperson of Cadila Pharma confirmed [...]
Read the full article →